Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase. METHODS: We randomly assigned patients with HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine, who had or did not have brain metastases, to receive either tucatinib or placebo, in combination with trastuzumab and capecitabine. The primary end point was progression-free survival among the first 480 patients who underwent randomization. Secondary end points, assessed in the total population (612 patients), included overall survival, progression-free survival among patients with brain metastases, confirmed objective response rate, and safety. RESULTS: Progression-free survival at 1 year was 33.1% in the tucatinib-combination group and 12.3% in the placebo-combination group (hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI], 0.42 to 0.71; P<0.001), and the median duration of progression-free survival was 7.8 months and 5.6 months, respectively. Overall survival at 2 years was 44.9% in the tucatinib-combination group and 26.6% in the placebo-combination group (hazard ratio for death, 0.66; 95% CI, 0.50 to 0.88; P = 0.005), and the median overall survival was 21.9 months and 17.4 months, respectively. Among the patients with brain metastases, progression-free survival at 1 year was 24.9% in the tucatinib-combination group and 0% in the placebo-combination group (hazard ratio, 0.48; 95% CI, 0.34 to 0.69; P<0.001), and the median progression-free survival was 7.6 months and 5.4 months, respectively. Common adverse events in the tucatinib group included diarrhea, palmar-plantar erythrodysesthesia syndrome, nausea, fatigue, and vomiting. Diarrhea and elevated aminotransferase levels of grade 3 or higher were more common in the tucatinib-combination group than in the placebo-combination group. CONCLUSIONS: In heavily pretreated patients with HER2-positive metastatic breast cancer, including those with brain metastases, adding tucatinib to trastuzumab and capecitabine resulted in better progression-free survival and overall survival outcomes than adding placebo; the risks of diarrhea and elevated aminotransferase levels were higher with tucatinib. (Funded by Seattle Genetics; HER2CLIMB ClinicalTrials.gov number, NCT02614794.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This was achieved at the expense of increased toxicity, mostly diarrhoea and elevated aminotransferase levels of grade ≥3, but did not lead to frequent treatment discontinuation.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [62]
In the citing paper
“Tucatinib, a highly selective inhibitor of the HER2 tyrosine kinase, used in combination with capecitabine and trastuzumab in a population of ABC patients pretreated with trastuzumab, pertuzumab and trastuzumab emtansine (T-DM1), demonstrated improvement of PFS (median 7.8 months versus 5.6 months, HR 0.54; 95% CI 0.42-0.71, P < 0.001) and OS (median 21.9 months versus 17.4 months, HR 0.66; 95% CI”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [62]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network (NCCN).
Wood, E. H. (2004) · Journal of the Medical Library Association JMLA · Cited by 2,845
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationBendell, J. C., Domchek, S. M., Burstein, H. J., Harris, L., Younger, J., Kuter, I., Bunnell, C., Rue, M., Gelman, R., & Winer, E. (2003) · Cancer · doi:10.1002/cncr.11436 · Cited by 1,320
Self-citation4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationSwain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Bachelot, T., Romieu, G., Campone, M., Diéras, V., Cropet, C., Dalenc, F., Jimenez, M., Le Rhun, E., Pierga, J.-Y., Gonçalves, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70432-1 · Cited by 737
Self-citationLin, N. U., Diéras, V., Paul, D., Lossignol, D., Christodoulou, C., Stemmler, H.-J., Roché, H., Liu, M. C., Greil, R., Ciruelos, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1080 · Cited by 658
Self-citationOwens, M. A., Horten, B. C., & Da Silva, M. M. (2004) · Clinical Breast Cancer · doi:10.3816/cbc.2004.n.011 · Cited by 657
Schnipper, L. E., Davidson, N. E., Wollins, D. S., Blayney, D. W., Dicker, A. P., Ganz, P. A., Hoverman, J. R., Langdon, R., Lyman, G. H., Meropol, N. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2518 · Cited by 655
Krop, I. E., Lin, N. U., Blackwell, K., Guardino, E., Huober, J., Lu, M., Miles, D., Samant, M., Welslau, M., & Diéras, V. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu486 · Cited by 394
Self-citationBrufsky, A. M., Mayer, M., Rugo, H. S., Kaufman, P. A., Tan-Chiu, E., Tripathy, D., Tudor, I. C., Wang, L. I., Brammer, M. G., Shing, M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2962 · Cited by 386
Randomization in Clinical Trials: Theory and Practice
Rosenberger, W. F., & Lachin, J. M. (2002) · Cited by 373
Freedman, R. A., Gelman, R. S., Anders, C. K., Melisko, M. E., Parsons, H. A., Cropp, A. M., Silvestri, K., Cotter, C. M., Componeschi, K. P., Marte, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01511 · Cited by 341
Self-citationPivot, X., Manikhas, A., Żurawski, B., Chmielowska, E., Karaszewska, B., Allerton, R., Chan, S., Fabi, A., Bidoli, P., Gori, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1794 · Cited by 242
Leyland-Jones, B. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8481 · Cited by 233
Pestalozzi, B. C., Holmes, E., de Azambuja, E., Metzger-Filho, O., Hogge, L., Scullion, M., Láng, I., Wardley, A., Lichinitser, M., Sanchez, R. I. L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70017-2 · Cited by 210
Self-citationCronin, K. A., Harlan, L. C., Dodd, K. W., Abrams, J. S., & Ballard-Barbash, R. (2010) · Cancer Investigation · doi:10.3109/07357907.2010.496759 · Cited by 187
Murthy, R., Borges, V. F., Conlin, A., Chaves, J., Chamberlain, M., Gray, T., Vo, A., & Hamilton, E. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30256-0 · Cited by 170
Self-citationMoulder, S. L., Borges, V. F., Baetz, T. D., McSpadden, T., Fernetich, G., Murthy, R. K., Chavira, R., Guthrie, K., Barrett, E., & Chia, S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1496 · Cited by 157
Self-citationRandomization in Clinical Trials
Rosenberger, W. F., & Lachin, J. M. (2015) · Wiley series in probability and statistics · doi:10.1002/9781118742112 · Cited by 155
Sutherland, S., Ashley, S. E., Miles, D. W., Chan, S. Y. T., Wardley, A. M., Davidson, N. G. P., Bhatti, R., Shehata, M., Nouras, H., Camburn, T., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605586 · Cited by 140
Lin, N., Prowell, T. M., Tan, A. R., Kozak, M., Rosen, O., Amiri‐Kordestani, L., White, J. R., Sul, J., Perkins, L. M., Beal, K., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.0761 · Cited by 131
Self-citationOlson, E. M., Najita, J., Sohl, J. J., Arnaout, A., Burstein, H. J., Winer, E. P., & Lin, N. (2013) · The Breast · doi:10.1016/j.breast.2012.12.006 · Cited by 128
Self-citationSaura, C., Oliveira, M., Feng, Y.-H., Dai, M.-S., Hurvitz, S. A., Kim, S.-B., Moy, B., Delaloge, S., Gradishar, W. J., Masuda, N., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.1002 · Cited by 99
Self-citationRugo, H. S., Im, S.-A., Wright, G. L. S., Escriva-de-Romani, S., DeLaurentiis, M., Cortes, J., Bahadur, S. W., Haley, B. B., Oyola, R. H., Riseberg, D. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.1000 · Cited by 80
Self-citationA group sequential Holm procedure with multiple primary endpoints
Ye, Y., Li, A., Liu, L., & Yao, B. (2012) · Statistics in Medicine · doi:10.1002/sim.5700 · Cited by 48
Giordano, S. H., Temin, S., & Davidson, N. E. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00290 · Cited by 27
Research works printed but not linked: 1
- Pheneger T, Bouhana K, Anderson D, et al. In vitro and in vivo activity of ARRY-380: a potent, small molecule inhibitor of ErbB2. Cancer Res 2009;69:1795-1795. abstract.
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Loibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,648
Self-citationGennari, A., André, F., Barrios, C. H., Cortés, J., de Azambuja, E., DeMichele, A., Dent, R., Fenlon, D., Gligorov, J., Hurvitz, S. A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.019 · Cited by 1,417
Self-citation5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
“005) compared with patients treated with capecitabine/trastuzumab/placebo.(62) This was achieved at the expense of increased toxicity, mostly diarrhoea and elevated aminotransferase levels of grade 3, but did not lead to frequent treatment discontinuation.”
Self-citationMosele, F., Remon, J., Mateo, J., Westphalen, C. B., Barlesi, F., Lolkema, M. P., Normanno, N., Scarpa, A., Robson, M., Meric-Bernstam, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.014 · Cited by 1,186
Metadata
- Authors
- Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., Bedard, P. L., Oliveira, M., Jakobsen, E., Bachelot, T., Shachar, S. S., Müller, V., Braga, S., Duhoux, F. P., Greil, R., Cameron, D., Carey, L. A., Curigliano, G., Gelmon, K., Hortobagyi, G., Krop, I., Loibl, S., Pegram, M., Slamon, D., Palanca-Wessels, M. C., Walker, L., Feng, W., & Winer, E. P.
- Affiliations
- Royal Marsden NHS Foundation Trust (GB)
- From M.D. Anderson Cancer Center, Houston (R.K.M., G.H.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S. Loi); the Royal Marsden NHS Foundation Trust, London (A.O.), and Edinburgh Cancer Research Centre, Edinburgh (D.C.) — both in the United Kingdom; Winship Cancer Institute, Atlanta (E.P.); Sarah Cannon Research Institute/Tennessee Oncology–Nashville (E.H.) and Vanderbilt University Medical Center (V.A.), Nashville; University of California, Los Angeles, Medical Center–Jonsson...
- BC Cancer Agency (CA)
- ORCID
- Murthy, Rashmi K.
- Loi, Sherene
- Okines, Alicia
- Hamilton, Erika
- Hurvitz, Sara A.
- Borges, Virginia
- Abramson, Vandana
- Anders, Carey
- Bedard, Philippe L.
- Oliveira, Mafalda
- Jakobsen, Erik
- Bachelot, Thomas
- Shachar, Shlomit S.
- Müller, Volkmar
- Braga, Sofia
- Duhoux, Francois P.
- Greil, Richard
- Cameron, David
- Curigliano, Giuseppe
- Gelmon, Karen
- Krop, Ian
- Loibl, Sibylle
- Pegram, Mark
- Slamon, Dennis
- Palanca-Wessels, M. Corinna
- Feng, Wentao
- Winer, Eric P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-13
- Volume
- 382
- Issue
- 7
- Pages
- 597-609
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2995808512
- Cited by
- 1,326
- References
- 29
- Citations by year
- 2026: 118 · 2025: 158 · 2024: 203 · 2023: 197 · 2022: 252 · 2021: 244 · 2020: 152
- FWCI
- 67.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- UNC Libraries
- Funders
- Seattle Genetics
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- tucatinib, HER2-positive metastatic breast cancer, trastuzumab, capecitabine, HER2 tyrosine kinase inhibitor, brain metastases, progression-free survival, overall survival, pertuzumab, trastuzumab emtansine, HER2-targeted therapy, diarrhea, hand-foot syndrome
- MeSH terms
- Trastuzumab, Capecitabine, Progression-Free Survival, Aged, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Breast Neoplasms, Diarrhea, Double-Blind Method, Female, Humans, Middle Aged, Oxazoles, Protein-Tyrosine Kinases, Pyridines, Quinazolines, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Kaplan-Meier Estimate, Consolidation Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.